Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)
- 1 January 1979
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 2 (2) , 101-105
- https://doi.org/10.1007/bf00254081
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- ABVD TREATMENT OF MOPP FAILURES IN HODGKINS-DISEASE - RE-EXAMINATION OF GOALS OF SALVAGE THERAPY1978
- The treatment of combination chemotherapy-resistant Hodgkin disease with single-agent vinblastineAmerican Journal of Hematology, 1978
- A New Combination Chemotherapy for Resistant Hodgkin DiseaseJAMA, 1977
- COMBINED CHEMOTHERAPY (MOPP OR ABVD)-RADIOTHERAPY APPROACH IN ADVANCED HODGKINS-DISEASE1977
- COMBINATION THERAPY FOR ADVANCED RESISTANT HODGKIN'S DISEASEThe Lancet, 1975
- Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease.1975
- Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPPCancer, 1975
- Recent trends in the medical treatment of Hodgkin's diseasePublished by Elsevier ,1975
- Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapyClinical Pharmacology & Therapeutics, 1972
- Combination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseAnnals of Internal Medicine, 1970